Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quizartinib sub-study in pediatric FLT3-ITD positive, NPM1 wild-type AML
NL-OMON60327Phase 2Recruiting
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of quizartinib in acute myeloid leukemia (AML) (2 arms), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoints: MRD negativity after up to 2 induction courses and Dose-limiting toxicities and RP2D determination. Started Dec 2023; status: recruiting.
02
Drugs
quizartinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON60327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60327.